https://www.scipublications.com/journal/index.php/wjcor <p>World Journal of Cancer and Oncology Research(WJCOR) is an international peer-reviewed journal that publishes original and high-quality research papers in all areas of cancer and oncology. As an important academic exchange platform, scientists and researchers can know the most up-to-date academic trends and seek valuable primary sources for reference.</p> en-US World Journal of Cancer and Oncology Research https://www.scipublications.com/journal/index.php/wjcor/article/view/833 <p>This article focuses on primary liver cancer and tries to present a possible CBT-Cognitive Behavioral Therapy group intervention of 6 sessions and a follow up based on a scientific review. We present an international national data analyze of the problem and characterize it in terms of symptoms, diagnosis and treatment. From the psychological point of view our goal is to show and reflect on the connection between theory and practice in research mental health and the quality of life of people suffering from liver cancer. CBT interventions programme have shown efficacy and effectiveness on improving quality of life of patients.</p> Luísa Soares Matilde Silva Copyright (c) 2024 World Journal of Cancer and Oncology Research 2024-03-06 2024-03-06 1 12 https://www.scipublications.com/journal/index.php/wjcor/article/view/909 <p>Myeloproliferative neoplasms (MPNs) are hematological disorders affecting myeloid stem cells. They are classified as Philadelphia (Ph) chromosome positive-chronic myeloid leukemia, and Ph-negative polycythemia vera, essential thrombocythemia, primary myelofibrosis, chronic neutrophilic leukemia, chronic eosinophilic leukemia, juvenile myelomonocytic leukemia, and MPN unclassifiable. This review is mainly focused on the Ph-negative MPNs namely, PV, ET, and PMF. These affect both males and females with a slight male predominance, with patients mainly presenting in the seventh decade. Patients often present with thrombotic events resulting in complications that lower survival rates. The major driver mutations that have been identified in MPNs are <em>JAK2 </em>Exon 14, <em>JAK2 </em>Exon 12, <em>MPL </em>Exon 10, and<em> CALR </em>Exon 9. The importance of these driver mutations gives due recognition to their inclusion into the 2022 diagnostic criteria of the MPN WHO Classification. However, other non-driver mutations have also been reported, especially in triple-negative cases. These mutations lead to downstream constitutive activation of the JAK/STAT signaling pathway, as well as the MAPK, and PI3K/Akt pathways. Insights into the molecular pathogenesis of MPN and its association with <em>JAK2</em>, <em>CALR</em>, and <em>MPL</em> mutations have identified JAK2 as a rational therapeutic target. Thus, as an approach to MPN therapy, JAK2 inhibitors, such as ruxolitinib, have been shown to effectively inhibit JAK2, and are currently in clinical trials in combination with other drug classes. This review comprehensively examines the molecular markers of the main Ph-negative MPNs, as well as diagnosis and treatment options.</p> Blessing Afolabi Amani Riwaz Jagathpriya Weerasena Senani Williams Thanuja Denipitiya Buddhika Somawardana Mishal Faizan Prasanna Galhena Copyright (c) 2024 World Journal of Cancer and Oncology Research 2024-05-28 2024-05-28 13 32